comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 20:52:17 - browse：1

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout LOUD podcast: mifepristone case, GLP

WSS

Why the world’s most expensive drug might be worth the price

The Readout: Lenmeldy, GLP

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Readout LOUD podcast: mifepristone case, GLP

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Food as medicine: Medically tailored meals may get standardized

After affirmative action ruling, medical educators look to 'holistic review'

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: mifepristone case, GLP

United colonoscopy coverage change 'may cost lives,' doctors say

White House launches permanent pandemic office

Psychedelics group wrestles with new pharma identity

How artificial intelligence is being used to detect, treat cancer

focus

Caitlin Bernard's story shows physicians can't shy from advocacy

Providers still hesitate to prescribe buprenorphine, study finds

Study says nonprofit hospitals fall short in charity care spending

Will generative AI in health care meet the fate of IBM's Dr. Watson?

There's no autism epidemic. It's an autism diagnosis epidemic

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

explore

hotspot

knowledge

knowledge